Delayed Onset Muscle SorenessNCT07812688
Effects of Allicin Pretreatment on Anti-oxidation Ability and Delayed Onset Muscle Soreness
A study testing allicin in people with Delayed Onset Muscle Soreness, run by Guangxi Normal University at 1 site in China.
Trial summary
To investigate the effects of allicin pretreatment on delayed onset muscle soreness (DOMS), muscle function, and oxidative stress following eccentric exercise Read more about this study
- Who is it for?
- Ages 18 to 24 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Delayed Onset Muscle Soreness
- What is being tested?
- allicin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- 1 Apr 2024to 30 Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 24 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Participants voluntarily agreed to join the study and signed informed consent forms.
- Male participants aged between 18 and 24 years.
- Physically healthy, with no history of major or congenital diseases.
- Normal results in routine physical examinations, with no history of severe musculoskeletal injuries.
- Physical fitness levels equivalent to those of typical university students majoring in sports.
- During the entire experiment, participants must not engage in any intense physical activities other than the specified exercise protocol.
Who cannot join
- Participants with poor compliance or those who violate the experimental requirements.
- Participants who are unwilling to cooperate and fail to complete the required data collection for the experiment.
- Participants who have taken anti-inflammatory or steroid medications within the past month.
- Participants who have experienced musculoskeletal injuries within the past two months.
Trial locations and contacts
1 site in 1 country.
About this study
To investigate the effects of allicin pretreatment on delayed onset muscle soreness (DOMS), muscle function, and oxidative stress following eccentric exercise
- Conditions
- Delayed Onset Muscle Soreness
- Being tested
- allicin, placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
allicinDrug
The garlic extract capsules were purchased from Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. (National Drug Approval No. H32025683).
Subjects took garlic extract capsules orally every day for 15 days before exercise, once per day, 4 capsules each time, equivalent to 80 mg/d
placeboDrug
The placebo was made by filling empty capsules with starch. The two were identical in packaging, appearance, color, and taste.
Group B: Subjects took the same dose of placebo (starch capsules) at 80 mg/d during the same period.
| Study group | Role | What they receive |
|---|---|---|
| allicin group | Experimental | The allicin group received garlic extract as an intervention Receives: Drug: allicin |
| placebo group | Placebo comparator | The placebo group received a placebo Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Subjective Pain Sensation
Subjective pain sensation was assessed using the Visual Analog Scale (VAS), which ranges from 0 mm (no pain) to 100 mm (worst imaginable pain). Higher scores indicate a worse outcome (greater pain intensity). Measurements were taken to evaluate the degree of Delayed Onset Muscle Soreness (DOMS) at the following time points: pre-medication (Pre-drug), pre-exercise (Pre-exercise), immediately post-exercise (Post-exercise), 24 hours post-exercise (24 h), 48 hours post-exercise (48 h), and 72 hours post-exercise (72 h).
Measured: Pre-medication, pre-exercise, immediately post-exercise, 24 hours, 48 hours, and 72 hours post-exercise.
Secondary outcomes (5)
Calf Circumference
Bilateral calf circumference was measured using a soft measuring tape (Hoechstmass, Germany) at the following time points: before medication (Pre-drug), before exercise (Pre-exercise), immediately after exercise (Post-exercise), 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise. Subjects lay prone on the examination table with legs slightly abducted and knees extended. The tape was placed horizontally around the thickest part of each calf, and the circumference was recorded in centimeters (cm). Each side was measured three times, and the average value was used for analysis.
Measured: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Vertical Jump Height
A vertical jump tester was used to measure the vertical jump height of the subjects at Pre-drug, Pre-exercise, Post-exercise, 24 h, 48 h, and 72 h. Subjects stood naturally on the jump platform with feet slightly apart, ready for testing. When "0.0" appeared on the screen of the electronic vertical jump platform (Hongkangda Sports Technology Development Co., Ltd., Beijing), and the subject heard "start," the test officially began. The subject bent their knees into a half-squat, swung their arms back, and forcefully jumped vertically upward. When the subject landed back on the platform, the display showed the corresponding value. The test was repeated three times, with the highest value taken.
Measured: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Posterior Calf Muscle Strength
The MicroFET2 handheld muscle strength tester (Hoggan, USA) was used to measure the posterior calf muscle strength of subjects at Pre-drug, Pre-exercise, Post-exercise, 24 h, 48 h, and 72 h. The subjects were in a prone position with arms placed at the sides, and the legs bent at 60° during the initial measurement. The tester placed the device under the Achilles tendon, and the subject resisted by flexing the calf for 8 seconds, then returned to the initial position. Each leg's muscle strength was tested five times, with the highest value recorded.
Measured: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Knee Joint Range of Motion
A goniometer (Changzhou Youbang Medical Rehabilitation Equipment Co., Ltd.) was used to measure the bilateral knee joint range of motion (ROM) in flexion at Pre-drug, Pre-exercise, Post-exercise, 24 h, 48 h, and 72 h. Subjects were prone (with hips and knees extended) on the edge of the examination bed, exposing the knee joint. The tester placed the axis of the goniometer at the fibular head of the knee joint, aligning the stationary arm parallel to the femoral shaft and the moving arm parallel to the fibular shaft. The moving arm followed the motion of the fibula, and the value of the knee joint's ROM was read at the terminal position
Measured: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Biochemical Index Sample Collection and Testing
At Pre-drug, Pre-exercise, post-exercise, 24 h, 48 h, and 72 h, 4 ml of median cubital vein blood was collected from each subject into an anticoagulant tube. The sample was centrifuged using a benchtop high-speed centrifuge (temperature: 4°C, 1000 rpm/min) for 15 minutes, and the supernatant was transferred to an EP tube and stored at -80°C for further testing. The thiobarbituric acid (TBA) method was used to measure the MDA content, while the T-AOC was determined using the ferric ion reducing/antioxidant power (FRAP) assay. The activity of CK-MM was measured by Enzyme-Linked Immunosorbent Assay (ELISA), and CK (Creatine Kinase) activity was measured using an optimized DGK colorimetric method. The MDA, T-AOC, and CK assay kits were purchased from Nanjing Jiancheng Bioengineering Institute, and the CK-MM assay kit was obtained from CUSABIO® (Wuhan Huamei Bioengineering Co., Ltd.).
Measured: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2026
- Study start1 Apr 2024
- Primary completion30 Jun 2024
- Study completion30 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Delayed Onset Muscle SorenessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Guangxi Normal University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jingzhi Zhang, Guangxi Normal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07812688
- Sponsor's protocol ID
- GXNU20230801003
- Status last verified
- Sep 2026
- First submitted
- 1 Sep 2026
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Allicin Pretreatment on Anti-oxidation Ability and Delayed Onset Muscle Soreness
- ClinicalTrials.gov ID
- NCT07812688
- Acronym / sponsor ID
- GXNU20230801003
- Conditions
- Delayed Onset Muscle Soreness
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Guangxi Normal UniversityUniversity, hospital or other
- Study start
- 1 Apr 2024 (actual)
- Primary completion
- 30 Jun 2024 (actual)
- Study completion
- 30 Jun 2024 (actual)
- First posted
- 10 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To investigate the effects of allicin pretreatment on delayed onset muscle soreness (DOMS), muscle function, and oxidative stress following eccentric exercise
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| allicin group | Experimental | Drug: allicinThe allicin group received garlic extract as an intervention |
| placebo group | Placebo comparator | Drug: placeboThe placebo group received a placebo |
Who may qualify
- Ages
- 18 to 24 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Participants voluntarily agreed to join the study and signed informed consent forms.
- Male participants aged between 18 and 24 years.
- Physically healthy, with no history of major or congenital diseases.
- Normal results in routine physical examinations, with no history of severe musculoskeletal injuries.
- Physical fitness levels equivalent to those of typical university students majoring in sports.
Key exclusion criteria (4 listed)
- Participants with poor compliance or those who violate the experimental requirements.
- Participants who are unwilling to cooperate and fail to complete the required data collection for the experiment.
- Participants who have taken anti-inflammatory or steroid medications within the past month.
- Participants who have experienced musculoskeletal injuries within the past two months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| allicinThe garlic extract capsules were purchased from Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. (National Drug Approval No. H32025683). Subjects took garlic extract capsules orally every day for 15 days before exercise, once per day, 4 capsules each time, equivalent to 80 mg/d | Drug | allicin group |
| placeboThe placebo was made by filling empty capsules with starch. The two were identical in packaging, appearance, color, and taste. Group B: Subjects took the same dose of placebo (starch capsules) at 80 mg/d during the same period. | Drug | placebo group |
Primary outcome
Subjective Pain Sensation
Time frame: Pre-medication, pre-exercise, immediately post-exercise, 24 hours, 48 hours, and 72 hours post-exercise.
Subjective pain sensation was assessed using the Visual Analog Scale (VAS), which ranges from 0 mm (no pain) to 100 mm (worst imaginable pain). Higher scores indicate a worse outcome (greater pain intensity). Measurements were taken to evaluate the degree of Delayed Onset Muscle Soreness (DOMS) at the following time points: pre-medication (Pre-drug), pre-exercise (Pre-exercise), immediately post-exercise (Post-exercise), 24 hours post-exercise (24 h), 48 hours post-exercise (48 h), and 72 hours post-exercise (72 h).
5 secondary outcomes
Calf Circumference
Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Vertical Jump Height
Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Posterior Calf Muscle Strength
Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Knee Joint Range of Motion
Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Biochemical Index Sample Collection and Testing
Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Delayed Onset Muscle Soreness
Recruiting
Shower Gel and Participant-Reported Post-Exercise Soreness in Regular Exercisers
Post-Exercise Recovery, Muscle Soreness
Recruiting
Mineral-Infused Clothing for Recovery From Muscle Soreness and Muscle Damage After Exercise
Delayed Onset Muscle Soreness, Exercise-Induced Muscle Damage
Not yet recruiting
Clinical and MRI Characteristics of Delayed Onset Muscle Soreness (DOMS) of the Shoulder Rotator Muscles Induced by Eccentric Exercise: An Exploratory Prospective Experimental Study
Delayed Onset Muscle Soreness Experimentally Induced
Recruiting
Effects of Kinesio Tape on Delayed Onset Muscle Soreness
Delayed Onset Muscle Soreness
Not yet recruiting
Therapeutic Ultrasound for Muscle Recovery After Muscle Fatigue Exercise
Muscle Fatigue (C23.888.592.612.612), Delayed Onset Muscle Soreness (DOMS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing allicin in people with Delayed Onset Muscle Soreness, run by Guangxi Normal University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Subjective Pain Sensation (time frame: Pre-medication, pre-exercise, immediately post-exercise, 24 hours, 48 hours, and 72 hours post-exercise.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.